gemcitabine + cisplatin + carboplatin

gemcitabine + cisplatin + carboplatin is a combination chemotherapy regimen consisting of the pyrimidine antimetabolite gemcitabine and the platinum-based alkylating-like agents cisplatin and carboplatin. In the context of the Phase 3 NEC-UC2 clinical trial (NCT06879145) sponsored by Suzhou Suncadia Biopharmaceuticals, this combination serves as the standard-of-care control arm for patients with previously untreated locally advanced or metastatic urothelial carcinoma. Gemcitabine acts as a prodrug that, once phosphorylated, inhibits ribonucleoside reductase and competes with dCTP for incorporation into DNA, leading to chain termination. Cisplatin and carboplatin exert their cytotoxic effects by forming covalent DNA adducts and cross-links, which inhibit DNA replication and transcription, ultimately inducing apoptosis in rapidly dividing cancer cells.

Brand names

Paraplatin

Other names

Gem-CisGem-Carbo